- Home
- PLX vs ARL Comparison
PLX vs ARL Comparison
Compare PLX & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- ARL
- Stock Information
- Founded
- PLX 1993
- ARL 1999
- Country
- PLX United States
- ARL United States
- Employees
- PLX N/A
- ARL N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- ARL Building operators
- Sector
- PLX Health Care
- ARL Real Estate
- Exchange
- PLX Nasdaq
- ARL Nasdaq
- Market Cap
- PLX 204.9M
- ARL 245.7M
- IPO Year
- PLX 1998
- ARL N/A
- Fundamental
- Price
- PLX $2.19
- ARL $16.58
- Analyst Decision
- PLX Strong Buy
- ARL
- Analyst Count
- PLX 1
- ARL 0
- Target Price
- PLX $15.00
- ARL N/A
- AVG Volume (30 Days)
- PLX 934.1K
- ARL 1.2K
- Earning Date
- PLX 11-13-2025
- ARL 11-06-2025
- Dividend Yield
- PLX N/A
- ARL N/A
- EPS Growth
- PLX N/A
- ARL N/A
- EPS
- PLX 0.08
- ARL 0.36
- Revenue
- PLX $61,948,000.00
- ARL $50,491,000.00
- Revenue This Year
- PLX $14.53
- ARL N/A
- Revenue Next Year
- PLX $75.77
- ARL N/A
- P/E Ratio
- PLX $28.28
- ARL $46.41
- Revenue Growth
- PLX 62.79
- ARL 1.75
- 52 Week Low
- PLX $1.16
- ARL $9.43
- 52 Week High
- PLX $3.10
- ARL $18.00
- Technical
- Relative Strength Index (RSI)
- PLX 46.99
- ARL 57.07
- Support Level
- PLX $2.25
- ARL $15.66
- Resistance Level
- PLX $2.40
- ARL $16.89
- Average True Range (ATR)
- PLX 0.14
- ARL 0.29
- MACD
- PLX -0.02
- ARL 0.12
- Stochastic Oscillator
- PLX 40.70
- ARL 79.58
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.